Drug intelligence / Profile preview

AN0533

Development stage: Unknown
Lead developer: Beijing Anlong Biopharmaceutical
Modality: Small Molecules

Overview

AN0533 is a small molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, currently under development by Beijing Anlong Biomedical for the treatment of migraine. CGRP is a potent neuropeptide and a key mediator in the pathophysiology of migraine, involved in vasodilation and the transmission of pain signals. By blocking the CGRP receptor, AN0533 aims to prevent or alleviate migraine attacks. The drug is currently in Phase 1 clinical development, representing a targeted therapeutic approach within the 'gepant' class of migraine medications.

Targets

Calcitonin gene-related peptide type 1 receptor

Beyond the preview

Go deeper on AN0533.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN0533.

Explore the full profile